Aquestive Therapeutics: Bullish Roadmap After Q2 Earnings [Seeking Alpha]
Aquestive Therapeutics, Inc. (AQST)
Last aquestive therapeutics, inc. earnings: 3/11 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.aquestive.com/investor-relations
Company Research
Source: Seeking Alpha
Summary Aquestive Therapeutics Q2 earnings report showed significant beats in EPS and revenue, with a 52% year-over-year revenue increase. The company reported improved operational efficiency and profitability, with a positive non-GAAP adjusted EBITDA of $1.8M and $89.9M in cash, extending their cash runway into 2026. Aquestive provided updates on Anaphylm's progress towards an NDA submission in early 2025, as well as advancements in their Adrenaverse platform and Libervant's market access. AQST is now trading above my previous Buy Threshold. I update my Buy and Sell Targets for AQST. teekid It has been over four months since my last Aquestive Therapeutics ( NASDAQ: AQST article , where I went over Anaphylm's Phase III data and the possibility for the company to send in an NDA to the FDA this year. Furthermore, I Recommended For You About AQST Stock
Show less
Read more
Impact Snapshot
Event Time:
AQST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AQST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AQST alerts
High impacting Aquestive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AQST
News
- Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27thGlobeNewswire
- Aquestive Therapeutics to Participate in Two Upcoming Investor ConferencesGlobeNewswire
- Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025 [Seeking Alpha]Seeking Alpha
- Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™GlobeNewswire
AQST
Earnings
- 8/6/24 - Beat
AQST
Sec Filings
- 9/9/24 - Form 8-K
- 8/14/24 - Form 8-K
- 8/12/24 - Form 4
- AQST's page on the SEC website